Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IDRCB 2019-A01679-48 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.
The collection of data from patients with CHC and cholangiocarcinomas who are cancers with poor prognosis is a major challenge to improve patients'care (diagnosis, prognosis); facilitate the search for new therapeutic targets and the follow-up of clinical studies; and develop personalized treatments.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients with Hepatocellular carcinoma | |||
| patients with Cholangiocarcinoma |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Hepatocellular carcinoma and Cholangiocarcinoma : Overall survival is defined as the survival 5 years after the inclusion. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Hepatocellular carcinoma :Overall survival is defined as the survival after 5 years of inclusion. | 5 years |
| Disease free survival | Cholangiocarcinoma : 2 and 5 years after surgical resection |
Not provided
Inclusion Criteria:
Inclusion Criteria :
Cholangiocarcinoma:
- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease
Hepatocellular carcinoma:
Exclusion Criteria:
- Lack of patient non-opposition
Not provided
Not provided
Not provided
Not provided
All patients with hepatocellular carcinoma or cholangiocarcinoma treated in Saint-Antoine hospital
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marie LEQUOY, MD | Contact | +330149283154 | marie.lequoy@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Marie LEQUOY, MD | AssistancePublique-Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Serviec hépatologie-Hôpital Saint Antoine | Recruiting | Paris | 75012 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018281 | Cholangiocarcinoma |
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2 and 5 years |
| Progression time under chemotherapy | Cholangiocarcinoma : Time of progression under chemotherapy is defined by the delay between the start of chemotherapy and tumor progression (appearance of a new lesion or increase in size of more than 30%) | Time of progression under chemotherapy up to 5 years |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |